PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
▲ Peaking Health

Tirzepatide in Adolescents With Obesity The SURMOUNT-ADOLESCENTS Randomized Clinical Trial

Tirzepatide led to substantial BMI reductions in adolescents with obesity during the phase III SURMOUNT-ADOLESCENTS trial.

5sources
5articles
3velocity
+0%since first seen
1h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

MedPage Today reported that once-weekly tirzepatide, known as Zepbound, paired with a healthy lifestyle intervention, yielded an 18.5% mean BMI reduction at week 72 compared with a 0.5% increase with a placebo. The trial met its primary endpoint for superiority, showing an estimated treatment difference of -19.0 percentage points. Aaron S. Kelly, PhD, of the University of Minnesota Medical School and his colleagues presented these findings at the ObesityWeek annual meeting while simultaneously publishing them in JAMA. According to MedPage Today, the trial enrolled 160 adolescents aged 12 to less than 18 years across 31 medical research centers and hospitals in Canada, the Czech Republic, Israel, Italy, Poland, and the United States from October 2023 to June 2026. Participants had obesity or overweight with obesity-related complications. At baseline, the average participant age was 14.6 years, 61.9% were female, the mean weight was 242 lb, and the mean BMI was 38.6. Following a 12-week healthy lifestyle lead-in, participants were randomized 2:1 to receive subcutaneous tirzepatide or a placebo alongside ongoing diet and physical activity counseling. The tirzepatide group escalated to a maximum tolerated dose of 5, 10, or 15 mg. MedPage Today noted that 61.6% of trial completers reached the 15-mg dose at week 72. All 10 key secondary outcomes significantly favored tirzepatide, including reductions in waist circumference and body weight alongside improvements in physical functioning. Over half of the participants treated with tirzepatide, specifically 53.5%, no longer met the clinical threshold for obesity at week 72, compared with 7.1% of those taking the placebo. Furthermore, 48.1% of tirzepatide-treated participants achieved at least a 20% reduction in BMI. Gastrointestinal events were reported as the most common adverse events, affecting 81.5% of the tirzepatide group compared with 54.9% of the placebo group. Most of these events were mild to moderate and occurred during dose escalation. Among participants who received at least one tirzepatide dose, 9.3% discontinued due to adverse events, while no participants in the placebo group discontinued for that reason. In an accompanying editorial, William Heerman, MD, MPH, of Vanderbilt Health and his colleagues cautioned against a reflexive dose escalation to the maximum tolerated dose, suggesting instead that clinicians individualize titration based on treatment response, side effects, and nutritional adequacy. Editorialists also pointed out a lack of racial and ethnic diversity in the trial, noting that participants were 83.4% white and 96.9% non-Hispanic.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 53m ago.

Quick answers

What is the primary finding of the SURMOUNT-ADOLESCENTS trial?

Tirzepatide led to an 18.5% mean BMI reduction at week 72 compared to a 0.5% increase with a placebo.

Who was eligible for the tirzepatide adolescent obesity study?

Adolescents ages 12 to under 18 with obesity or overweight plus at least one weight-related complication were enrolled.

What were the most common side effects of tirzepatide in the trial?

Gastrointestinal events were the most common adverse events, occurring in 81.5% of tirzepatide-treated participants.

Coverage (5)

Topics

Related trends

▲ Peaking Health

Maternal and early life obesity programs CD4

Recent scientific studies reveal that early-life obesity and high-fat diets permanently impair developing immune cells and vaccine efficacy.

7 sources 9 articles v 6 9h ago
◼ Archived Business

The GLP-1 boom has a dark side

FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.

5 sources 5 articles v 14 3d ago